Research programme: 17-beta hydroxysteroid dehydrogenase inhibitors - Schering-Plough
Alternative Names: 17β-HSD3 inhibitors; 17β-hydroxysteroid dehydrogenase type 3 inhibitors; SCH 391; SCH 659Latest Information Update: 25 Aug 2009
At a glance
- Originator Schering-Plough
- Class
- Mechanism of Action Hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 25 Aug 2009 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
- 06 May 2005 Preclinical trials in Prostate cancer in USA (unspecified route)
- 06 May 2005 Data presented at the 96th Annual Meeting of the American Association for Cancer Research (AACR-2005) have been added to the Cancer pharmacodynamics section ,,